Johnson & Johnson announced new data from its oncology pipeline at the 2025 European Lung Cancer Congress (ELCC), highlighting the Phase 3 MARIPOSA study results. The study showed that the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) significantly improves overall survival compared to osimertinib in first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). This breakthrough could extend patient survival by over a year, reshaping treatment expectations.

Additional findings include the Phase 2 COCOON study, which evaluates a proactive dermatologic regimen for patients receiving RYBREVANT, and the PALOMA-2 study, which explores switching to a subcutaneous formulation of amivantamab. These advancements reinforce Johnson & Johnson’s commitment to developing innovative, chemotherapy-free regimens that enhance patient outcomes and quality of life.